@azel
Die News von vorgestern bedeutete nur, dass ein Kooperationsabkommen mit einer kalifornischen Firma (Trifocal Group) nicht zustandegekommen ist. Centrex wird also in Zukunft weiter allein an der Entwicklung der Single Molecule Nucleic Acid Detection (SMD) arbeiten. Das finde ich eigentlich gar nicht so schlecht, denn dann gehen die zu erwartenden Gewinne nicht durch 2, sondern bleiben allein bei Centres.
Und hier gute News von gestern nachmittag:
"Centrex Retains First American Financial Group
WEDNESDAY, MARCH 03, 2004 01:28 PM
TULSA, Okla., Mar 3, 2004 (BUSINESS WIRE) -- Centrex, Inc. (OTCBB:CNEX) today announced that FIRST AMERICAN FINANCIAL GROUP, a private equity firm with offices in New York, has been retained to act as a financial consultant for the Company. Centrex has signed a term sheet with FIRST AMERICAN for up to $3.5 million in funding which includes an initial bridge loan of $500,000. The financing is contingent upon entering into definitive documentation. FIRST AMERICAN is a boutique Financial Services firm specializing in procuring capital for emerging growth small-cap and micro-cap companies.
"We are pleased to be associated with Centrex, a company that is in the process of developing a technology to provide for the immediate detection of agents that could be used in bioterrorism or biowarfare against the U.S.," stated Bill Rogers, Managing Director of FIRST AMERICAN.
Centrex owns the exclusive worldwide license to develop, manufacture and market the Single Molecule Nucleic Acid Detection (SMD) technology developed at Los Alamos National Laboratories. SMD offers important advantages over existing DNA and RNA detection methods as well as culture-based test methods for the detection and identification of bacteria and viruses.
SMD technology, in combination with an easy-to-operate lab card device and integrated reader, is expected to be responsive to the need for rapid, user friendly and cost effective solutions for point-of-use analyses of a variety of bacterial and viral organisms. This unique technology eliminates the need for amplification of the target DNA by recognizing the unique DNA or RNA fingerprint of the target organism. This reduces the possibility of false positive and negative test results -- common concerns frequently identified with other test procedures.
Centrex is currently developing a fully automated, network-capable system for detecting microbial contamination in air, food and water. The proposed device is a simultaneous multi-channel detection system that is compact, fully automated and capable of monitoring the presence of biological agents in air, food and water."
Die Finanzierung der Entwicklungsarbeiten bleibt also vollständig gesichert! Das war ja in dem Bericht der deutschen Wirtschaftsprüfungsgesellschaft der einzige Punkt, der gegen Centrex sprechen könnte: das möglicherweise Finanzierungsprobleme auftauchen könnten. Centrex hat in dieser Beziehung also weiter volles Vertrauen der Geldgeber!
|
Thread abonnieren
